CORRECTING and REPLACING NIMS’ Acceleration Platform Technology: an Effective Non-Invasive Strategy for Cardiac Protection

MIAMI--(BUSINESS WIRE)--Reissuing release dated Nov. 11, 2008 to add ticker symbol for searching purposes.

“In humans, this non-invasive device called Exer-Rest® has the configuration of a single or twin bed fitted with a memory foam mattress. Electrical actuation produces whole body periodic acceleration (WBPA) through repetitive head-foot movement of its incorporated platform at about 140 times per minute over a period of 45 minutes.”

The release reads:

NIMS’ ACCELERATION PLATFORM TECHNOLOGY: AN EFFECTIVE NON-INVASIVE STRATEGY FOR CARDIAC PROTECTION

Marvin A Sackner, M.D., Chief Executive Officer and Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that Drs. Jose A. Adams, Uryash, Wu and their associates at Mount Sinai Medical Center of Greater Miami presented three papers at the Annual Meeting of the American Heart Association held in New Orleans on November 8 and 9, 2008. These studies involved applications of NIMS’ patented acceleration therapeutic platform technology. Dr. Sackner stated that, “In humans, this non-invasive device called Exer-Rest^® has the configuration of a single or twin bed fitted with a memory foam mattress. Electrical actuation produces whole body periodic acceleration (WBPA) through repetitive head-foot movement of its incorporated platform at about 140 times per minute over a period of 45 minutes.”

Dr. Adams and associates showed that WBPA applied to small and large animal models increased the activity of the enzyme responsible for production of the beneficial substance, nitric oxide, from the blood vessels and heart. They further demonstrated the importance of these benefits in a well characterized rodent model of experimental myocardial infarction. In this model, approximately 55% of the heart at risk dies with occlusion of the coronary blood supply. Daily treatments with WBPA for three days prior to the induced coronary occlusion reduced the death of heart muscle from 55% in the untreated animals to 16% in the treated animals.

Dr. Adams commented that, “the strategy we employed in our experiments is called preconditioning, and the beneficial results are similar to the gold standard for its successful outcome. This gold standard, called ‘ischemic preconditioning,’ involves brief, episodic occlusions of the blood supply to the heart for subsequent protection prior to a prolonged coronary occlusion leading to a potential lethal myocardial infarction. In patients, preconditioning has limited applications since it is highly invasive and cannot be used acutely to minimize damage from an unpredictable myocardial infarction. It has most often been utilized for cardiac protection at the time of cardiac surgery or in the cardiac catheterization laboratory during percutaneous coronary interventions. ”

Dr. Adams also stated, “‘Ischemic preconditioning’ even though its value has been demonstrated in all animal species where it has been employed has not become a ‘standard of care’ owing to the highly invasive means necessary to carry it out. WBPA has the potential to become a ‘standard of care’ for the public since it is non-invasive, drug-free, and suitable for daily home use thereby potentially producing cardiac protection against the unpredictable, lethal myocardial infarction.”

The Exer-Rest^® is not currently available in the United States; however, NIMS submitted a 510(k) application for Exer-Rest^® to FDA in October 2008 that is under review for its intended use of providing aid to the circulation, and, temporary relief of aches and pains. This was done in order to meet FDA approval for the marketing of Exer-Rest^® in the United States. Exer-Rest is a CE0120 Class 2 device and can be marketed and sold in the common market and Canada.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, including the necessity of FDA approval to launch and Exer-Rest^® in the United States, which cannot be assured, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.